Keriann Cherofsky Sells 558 Shares of IQVIA (NYSE:IQV) Stock

IQVIA Holdings Inc. (NYSE:IQV) insider Keriann Cherofsky sold 558 shares of the stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total transaction of $136,827.18. Following the completion of the transaction, the insider directly owned 2,989 shares of the company’s stock, valued at approximately $732,932.69. The trade was a 15.73% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

IQVIA Trading Down 1.1%

Shares of NYSE IQV opened at $235.09 on Friday. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $251.36. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.75. The business’s 50 day moving average is $194.75 and its two-hundred day moving average is $187.20. The stock has a market capitalization of $38.70 billion, a P/E ratio of 29.17, a PEG ratio of 1.99 and a beta of 1.20.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.03 by $0.12. The business had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The company’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same period last year, the company earned $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, research analysts expect that IQVIA Holdings Inc. will post 11.61 EPS for the current year.

IQVIA announced that its Board of Directors has initiated a share repurchase program on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s leadership believes its shares are undervalued.

Hedge Funds Weigh In On IQVIA

Hedge funds and other institutional investors have recently made changes to their positions in the company. Ameliora Wealth Management Ltd. purchased a new position in shares of IQVIA during the fourth quarter valued at $25,000. International Assets Investment Management LLC purchased a new stake in IQVIA in the fourth quarter worth about $27,000. Gilpin Wealth Management LLC bought a new position in IQVIA during the 4th quarter worth about $27,000. CrossGen Wealth LLC purchased a new position in IQVIA during the 4th quarter valued at about $28,000. Finally, Activest Wealth Management raised its holdings in shares of IQVIA by 590.0% in the 4th quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 118 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

Key Stories Impacting IQVIA

Here are the key news stories impacting IQVIA this week:

• Positive Sentiment: William Blair upgraded IQVIA to “strong buy,” adding to the favorable analyst outlook. Ticker Report article
• Positive Sentiment: Robert W. Baird raised its IQVIA price target to $287, implying substantial upside from the cited trading level. JPMorgan and Stifel Nicolaus also expressed expectations for further appreciation. American Banking News article on Baird price target American Banking News article on JPMorgan forecast American Banking News article on Stifel outlook
• Positive Sentiment: IQVIA’s second-quarter results exceeded expectations, with adjusted earnings of $3.15 per share versus the $3.03 consensus and revenue of $4.37 billion versus $4.30 billion expected. Revenue increased 8.7% year over year, reinforcing the company’s growth profile. IQVIA Q2 2026 earnings call summary
• Neutral Sentiment: Analysts maintain a “moderate buy” consensus, indicating generally favorable sentiment but not unanimous conviction. IQVIA analyst consensus article
• Negative Sentiment: Two insiders sold shares on July 29: Keriann Cherofsky sold 558 shares for approximately $136,827, while Eric Sherbet sold 5,000 shares for about $1.25 million. Although both retain meaningful holdings, the transactions may create short-term investor concern. SEC insider sale filing for Keriann Cherofsky SEC insider sale filing for Eric Sherbet

Analyst Ratings Changes

Several research firms have recently issued reports on IQV. Mizuho raised their target price on shares of IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. HSBC reiterated a “buy” rating and set a $240.00 price target on shares of IQVIA in a report on Monday, July 6th. Morgan Stanley reissued an “equal weight” rating and issued a $200.00 price objective (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. Deutsche Bank Aktiengesellschaft set a $240.00 target price on IQVIA in a research note on Thursday, July 9th. Finally, Weiss Ratings upgraded IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, July 15th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $241.88.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.